Skip to main content
AB Science logo

AB Science — Investor Relations & Filings

Ticker · AB ISIN · FR0010557264 LEI · 969500U43TVR8CCVBJ97 PA Manufacturing
Open in API
Filings indexed 742 across all filing types
Latest filing 2022-04-29 Earnings Release
Country FR France
Listing PA AB

About AB Science

https://www.ab-science.com

AB Science is a clinical-stage pharmaceutical company that researches, develops, and markets protein kinase inhibitors for human and veterinary medicine. The company focuses on developing innovative drugs for diseases with high unmet medical needs. Its pipeline is centered on two main compounds: masitinib and AB8939. Masitinib, a highly selective tyrosine kinase inhibitor, is under investigation for treating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS) and Alzheimer's disease, as well as inflammatory diseases like mastocytosis. AB8939 is a microtubule destabilizer being developed for oncology, specifically for Acute Myeloid Leukemia (AML). The company also commercializes masitinib in veterinary medicine under the brand name Masivet®.

Recent filings

Filing Released Lang Actions
AB Science reports its revenues for the year 2021 and provides an update on its activities
Earnings Release Classification · 1% confidence The document is explicitly titled "AB SCIENCE PRESENTS ITS FINANCIAL INFORMATION AS OF DECEMBER 31, 2021 AND THE KEY EVENTS OF THE PERIOD" and contains detailed consolidated financial statements (P&L, Balance Sheet) for the year 2021, comparing them to 2020. This structure, covering a full fiscal year's performance and key operational updates, strongly indicates an Annual Report or a document closely related to it. However, the document is presented as a "PRESS RELEASE" and focuses on summarizing the results and key events, which often aligns with an Earnings Release (ER) or a comprehensive Interim/Annual Report. Since it covers the full year (December 31, 2021) and includes detailed financial tables, it is more comprehensive than a typical ER. Given the options, the most appropriate classification for a comprehensive annual financial summary released via press release, which often precedes or substitutes for the full 10-K filing in some contexts, is difficult to pinpoint perfectly between 10-K and ER. However, the presence of detailed, audited-style financial tables for the full year suggests it contains the core financial data of an Annual Report, even if presented as a press release summary. Since it is a comprehensive report for the full year, it is closer to the scope of a 10-K than a quarterly IR or a brief ER. If this were a summary preceding the 10-K, it would be an ER, but the depth of the financial tables suggests it is the primary annual financial disclosure. Given the comprehensive nature covering the entire year and detailed financials, I will classify it as the closest equivalent to the Annual Report disclosure, which is 10-K, recognizing that in some jurisdictions, this press release format might be the primary annual disclosure document if a formal 10-K is not the standard filing. FY 2021
2022-04-29 English
Rapport financier annuel 2021
Annual Report (ESEF) Classification · 1% confidence FY 2021
2022-04-29 French
Rapport financier annuel 2021
Annual Report (ESEF) Classification · 1% confidence FY 2021
2022-04-29 French
AB Science annonce la poursuite de l’étude de phase 2 évaluant le masitinib en combinaison avec l’isoquercétine dans le traitement du COVID-19, suite à l’avis formulé par le comité indépendant de revu
Regulatory Filings Classification · 1% confidence The document is titled "COMMUNIQUE DE PRESSE" (Press Release) and is dated April 28, 2022. It announces a specific operational update regarding a clinical trial (Phase 2 evaluation of Masitinib for COVID-19) following a recommendation from an Independent Data Monitoring Committee (IDMC). This type of announcement, detailing operational progress, clinical trial results/updates, or key business developments outside of mandatory periodic financial filings (like 10-K or IR), is typically classified as an Earnings Release (ER) if it contains key financial highlights, or more generally, a Regulatory Filing (RNS) if it's a general corporate announcement. Since this is a specific, time-sensitive announcement about clinical trial progress and committee recommendations, it functions similarly to an Earnings Release (ER) which often includes operational highlights, or it could be considered a general Regulatory Filing (RNS). Given the structure and content—a formal announcement of a significant operational milestone (IDMC recommendation to continue the trial)—it aligns best with the function of an Earnings Release (ER) or a general corporate update. However, since it is not explicitly reporting financial results (revenue, profit, EPS), the most appropriate general category for non-financial, material corporate news that must be disclosed is Regulatory Filings (RNS). If 'ER' is strictly for financial results, RNS is the best fit for this type of operational press release. Given the options, and recognizing this is a material, non-financial corporate update, RNS is the safest fallback, although in some contexts, a press release announcing trial progress might be grouped with ER if it's the primary news of the day. I will classify it as RNS as it is a general regulatory announcement/press release.
2022-04-28 French
AB Science announced the continuation of the Phase 2 study evaluating masitinib in combination with isoquercetin in COVID-19, following the recommendation of the Data and Safety Monitoring Board (DSMB
Regulatory Filings Classification · 1% confidence The document is a press release dated April 28, 2022, announcing a positive recommendation from the Data and Safety Monitoring Board (DSMB) to continue a Phase 2 clinical study evaluating masitinib for COVID-19. It details the study design, interim analysis results, and future plans for patient recruitment. This type of announcement, which communicates a significant operational or clinical development update to the market, typically falls under general regulatory announcements or investor relations communications. Since it is not a formal financial report (like 10-K or IR), a specific earnings release (ER), or a management discussion (MDA), and it is a direct communication of a material event, it best fits the 'Regulatory Filings' (RNS) category as a general regulatory announcement, or potentially an Investor Presentation (IP) if it were structured as a slide deck, but its format is a press release. Given the options, 'RNS' (Regulatory Filings) is the most appropriate fallback for a material, non-financial-specific press release. It is not an ER (no financial results), not an IP (it's a news release, not a presentation deck), and not an LTR (it's a study continuation, not a legal proceeding).
2022-04-28 English
Communication from AB Science following the decision of the Enforcement Committee of the French market regulator (AMF)
Legal Proceedings Report Classification · 1% confidence The document is a press release from AB Science dated March 29, 2022, communicating the decision of the French market regulator (AMF) Enforcement Committee regarding insider trading allegations and disclosure obligations related to capital increases and EMA opinion probability. This communication details the outcome of a regulatory investigation and the company's response, including the possibility of an appeal. This content directly relates to significant legal and regulatory matters involving the company. Among the provided categories, 'Legal Proceedings Report (LTR)' is the most appropriate fit, as it covers updates on significant lawsuits or regulatory actions, even if the outcome is favorable regarding some aspects, as the core subject is the regulatory ruling and associated penalty.
2022-03-29 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.